Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

147 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized Trial of Partial Gland Ablation with Vascular Targeted Phototherapy versus Active Surveillance for Low Risk Prostate Cancer: Extended Followup and Analyses of Effectiveness.
Gill IS, Azzouzi AR, Emberton M, Coleman JA, Coeytaux E, Scherz A, Scardino PT; PCM301 Study Group. Gill IS, et al. Among authors: azzouzi ar. J Urol. 2018 Oct;200(4):786-793. doi: 10.1016/j.juro.2018.05.121. Epub 2018 Jun 2. J Urol. 2018. PMID: 29864437 Free PMC article. Clinical Trial.
Final Results of a Phase I/II Multicenter Trial of WST11 Vascular Targeted Photodynamic Therapy for Hemi-Ablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Performed in the United States.
Taneja SS, Bennett J, Coleman J, Grubb R, Andriole G, Reiter RE, Marks L, Azzouzi AR, Emberton M. Taneja SS, et al. Among authors: azzouzi ar. J Urol. 2016 Oct;196(4):1096-104. doi: 10.1016/j.juro.2016.05.113. Epub 2016 Jun 9. J Urol. 2016. PMID: 27291652 Free PMC article. Clinical Trial.
The subclassification of papillary renal cell carcinoma does not affect oncological outcomes after nephron sparing surgery.
Bigot P, Bernhard JC, Gill IS, Vuong NS, Verhoest G, Flamand V, Reix B, Suer E, Gökce I, Beauval JB, Nouhaud FX, Eto M, Baco E, Matsugasumi T, Chowaniec Y, Rigaud J, Lenormand C, Pfister C, Hetet JF, Ploussard G, Roupret M, Léon P, Bakri AE, Larré S, Tillou X, Doerfler A, Descazeaud A, Koutlidis N, Schneider A, Sebe P, Ingels A, Azzouzi AR, Soulié M, Méjean A, Bensalah K, Patard JJ; members of the Kidney Cancer group of the CCAFU. Bigot P, et al. Among authors: azzouzi ar. World J Urol. 2016 Mar;34(3):347-52. doi: 10.1007/s00345-015-1634-0. Epub 2015 Jul 7. World J Urol. 2016. PMID: 26149352 Free PMC article.
Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial.
Azzouzi AR, Vincendeau S, Barret E, Cicco A, Kleinclauss F, van der Poel HG, Stief CG, Rassweiler J, Salomon G, Solsona E, Alcaraz A, Tammela TT, Rosario DJ, Gomez-Veiga F, Ahlgren G, Benzaghou F, Gaillac B, Amzal B, Debruyne FM, Fromont G, Gratzke C, Emberton M; PCM301 Study Group. Azzouzi AR, et al. Lancet Oncol. 2017 Feb;18(2):181-191. doi: 10.1016/S1470-2045(16)30661-1. Epub 2016 Dec 20. Lancet Oncol. 2017. PMID: 28007457 Free article. Clinical Trial.
Radical Prostatectomy after Vascular Targeted Photodynamic Therapy with Padeliporfin: Feasibility, and Early and Intermediate Results.
Pierrard V, Lebdai S, Kleinclauss F, Azzouzi AR, Terrier JE, Fortier E, Joniau S, Van Der Poel H, Salomon G, Casanova J, Medina-Lopez RA, Potiron E, Rigaud J, Vincendeau S, Rassweiler J, Villers A, Gaston R, Saussine C, Giai J, Gaillac B, Emberton M, Ruffion A. Pierrard V, et al. Among authors: azzouzi ar. J Urol. 2019 Feb;201(2):315-321. doi: 10.1016/j.juro.2018.08.084. J Urol. 2019. PMID: 30248343 Free article.
147 results